Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia

Hussein Algahtani, Bader Shirah, Hind Abobaker, Nebras Alghanaim, Fatemah Kamel

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	Clinical Neuropharmacology
DOIs	https://doi.org/10.1097/wnf.0000000000000305
Publication status	Published - Nov 2018

Access to Document

@article{85b2a3f7703a45fba37829507da755df,

title = "Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia",

author = "Hussein Algahtani and Bader Shirah and Hind Abobaker and Nebras Alghanaim and Fatemah Kamel",

year = "2018",

month = nov,

doi = "10.1097/wnf.0000000000000305",

language = "Undefined",

journal = "Clinical Neuropharmacology",

issn = "0362-5664",

publisher = "Lippincott Williams & Wilkins",

}

TY - JOUR

T1 - Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis

T2 - The Experience From Saudi Arabia

AU - Algahtani, Hussein

AU - Shirah, Bader

AU - Abobaker, Hind

AU - Alghanaim, Nebras

AU - Kamel, Fatemah

PY - 2018/11

Y1 - 2018/11

U2 - 10.1097/wnf.0000000000000305

DO - 10.1097/wnf.0000000000000305

M3 - Article

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

ER -